Researchers at the Mayo Clinic in Florida have discovered that an enzyme called PRSS3, or mesotrypsin, may help drive aggressive prostate cancer. Although they don't believe it is the only factor, they suggest it offers a new target for treatment, and have themselves developed a prototype compound that inhibits the enzyme's ability to promote the metastatic spread of the disease. They write about their study, the first to link the enzyme to prostate cancer, in the 18 December online issue of the journal Molecular Cancer Research...

More...